Trial Profile
Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms CapitalIN
- 14 Mar 2022 Planned End Date changed from 1 Jun 2020 to 1 Jun 2025.
- 14 Mar 2022 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2025.
- 20 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2020.